Kineta (KA) Reports Q1, Provides Update on Phase 1/2 VISTA-101 Trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Kineta (KA) Reports Q1, Provides Update on Phase 1/2 VISTA-101 Trial

Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities

May 15, 2024 4:01 PM EDT

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts

Favorable clinical safety and tolerability profile observed with no dose limiting toxicities and no evidence of CRS-associated cytokines observed at any dose level

Cleared fifth of six monotherapy cohorts and second of four combination cohorts

Kineta is actively exploring strategic alternatives to maximize value for all stakeholders

Received $500,000 investment from an existing investor

SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq:... More